Hemant Surgical Industries Ltd.

HSIL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSIL.BO stands at 3.1B. In comparison, VOEPL.BO has a market cap of 8.5B. Regarding current trading prices, HSIL.BO is priced at ₹293.65, while VOEPL.BO trades at ₹369.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSIL.BO currently has a P/E ratio of 40.98, whereas VOEPL.BO's P/E ratio is 111.56. In terms of profitability, HSIL.BO's ROE is +0.11%, compared to VOEPL.BO's ROE of +0.06%. Regarding short-term risk, HSIL.BO is more volatile compared to VOEPL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HSIL.BO.Check VOEPL.BO's competition here

HSIL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSIL.BO stands at 3.1B. In comparison, PREVEST.BO has a market cap of 5.4B. Regarding current trading prices, HSIL.BO is priced at ₹293.65, while PREVEST.BO trades at ₹445.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSIL.BO currently has a P/E ratio of 40.98, whereas PREVEST.BO's P/E ratio is 27.32. In terms of profitability, HSIL.BO's ROE is +0.11%, compared to PREVEST.BO's ROE of +0.19%. Regarding short-term risk, HSIL.BO is more volatile compared to PREVEST.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HSIL.BO.Check PREVEST.BO's competition here

HSIL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSIL.BO stands at 3.1B. In comparison, RAAJMEDI.BO has a market cap of 1.1B. Regarding current trading prices, HSIL.BO is priced at ₹293.65, while RAAJMEDI.BO trades at ₹85.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSIL.BO currently has a P/E ratio of 40.98, whereas RAAJMEDI.BO's P/E ratio is 14.07. In terms of profitability, HSIL.BO's ROE is +0.11%, compared to RAAJMEDI.BO's ROE of +0.29%. Regarding short-term risk, HSIL.BO is more volatile compared to RAAJMEDI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HSIL.BO.Check RAAJMEDI.BO's competition here

HSIL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSIL.BO stands at 3.1B. In comparison, CHOKSI.BO has a market cap of 831.5M. Regarding current trading prices, HSIL.BO is priced at ₹293.65, while CHOKSI.BO trades at ₹150.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSIL.BO currently has a P/E ratio of 40.98, whereas CHOKSI.BO's P/E ratio is 24.85. In terms of profitability, HSIL.BO's ROE is +0.11%, compared to CHOKSI.BO's ROE of +0.16%. Regarding short-term risk, HSIL.BO is less volatile compared to CHOKSI.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HSIL.BO.Check CHOKSI.BO's competition here

HSIL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSIL.BO stands at 3.1B. In comparison, KRETTOSYS.BO has a market cap of 582.5M. Regarding current trading prices, HSIL.BO is priced at ₹293.65, while KRETTOSYS.BO trades at ₹0.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSIL.BO currently has a P/E ratio of 40.98, whereas KRETTOSYS.BO's P/E ratio is 86.00. In terms of profitability, HSIL.BO's ROE is +0.11%, compared to KRETTOSYS.BO's ROE of +0.02%. Regarding short-term risk, HSIL.BO is less volatile compared to KRETTOSYS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HSIL.BO.Check KRETTOSYS.BO's competition here

HSIL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSIL.BO stands at 3.1B. In comparison, SHREEPAC.BO has a market cap of 484.5M. Regarding current trading prices, HSIL.BO is priced at ₹293.65, while SHREEPAC.BO trades at ₹125.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSIL.BO currently has a P/E ratio of 40.98, whereas SHREEPAC.BO's P/E ratio is 20.47. In terms of profitability, HSIL.BO's ROE is +0.11%, compared to SHREEPAC.BO's ROE of +0.18%. Regarding short-term risk, HSIL.BO is less volatile compared to SHREEPAC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HSIL.BO.Check SHREEPAC.BO's competition here

HSIL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSIL.BO stands at 3.1B. In comparison, KMSMEDI.BO has a market cap of 397.6M. Regarding current trading prices, HSIL.BO is priced at ₹293.65, while KMSMEDI.BO trades at ₹126.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSIL.BO currently has a P/E ratio of 40.98, whereas KMSMEDI.BO's P/E ratio is N/A. In terms of profitability, HSIL.BO's ROE is +0.11%, compared to KMSMEDI.BO's ROE of +0.08%. Regarding short-term risk, HSIL.BO is more volatile compared to KMSMEDI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HSIL.BO.Check KMSMEDI.BO's competition here

HSIL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSIL.BO stands at 3.1B. In comparison, GKB.BO has a market cap of 324M. Regarding current trading prices, HSIL.BO is priced at ₹293.65, while GKB.BO trades at ₹63.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSIL.BO currently has a P/E ratio of 40.98, whereas GKB.BO's P/E ratio is -6.48. In terms of profitability, HSIL.BO's ROE is +0.11%, compared to GKB.BO's ROE of -0.05%. Regarding short-term risk, HSIL.BO is less volatile compared to GKB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HSIL.BO.Check GKB.BO's competition here

HSIL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSIL.BO stands at 3.1B. In comparison, CSURGSU.BO has a market cap of 308.3M. Regarding current trading prices, HSIL.BO is priced at ₹293.65, while CSURGSU.BO trades at ₹86.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSIL.BO currently has a P/E ratio of 40.98, whereas CSURGSU.BO's P/E ratio is -15.91. In terms of profitability, HSIL.BO's ROE is +0.11%, compared to CSURGSU.BO's ROE of -0.03%. Regarding short-term risk, HSIL.BO is less volatile compared to CSURGSU.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HSIL.BO.Check CSURGSU.BO's competition here

HSIL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSIL.BO stands at 3.1B. In comparison, ADESHWAR.BO has a market cap of 303.1M. Regarding current trading prices, HSIL.BO is priced at ₹293.65, while ADESHWAR.BO trades at ₹18.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSIL.BO currently has a P/E ratio of 40.98, whereas ADESHWAR.BO's P/E ratio is 16.03. In terms of profitability, HSIL.BO's ROE is +0.11%, compared to ADESHWAR.BO's ROE of +0.04%. Regarding short-term risk, HSIL.BO is more volatile compared to ADESHWAR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HSIL.BO.Check ADESHWAR.BO's competition here

HSIL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSIL.BO stands at 3.1B. In comparison, SDL.BO has a market cap of 190.8M. Regarding current trading prices, HSIL.BO is priced at ₹293.65, while SDL.BO trades at ₹34.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSIL.BO currently has a P/E ratio of 40.98, whereas SDL.BO's P/E ratio is -9.12. In terms of profitability, HSIL.BO's ROE is +0.11%, compared to SDL.BO's ROE of +0.38%. Regarding short-term risk, HSIL.BO is more volatile compared to SDL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HSIL.BO.Check SDL.BO's competition here

HSIL.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSIL.BO stands at 3.1B. In comparison, NOVATEOR.BO has a market cap of 188.9M. Regarding current trading prices, HSIL.BO is priced at ₹293.65, while NOVATEOR.BO trades at ₹31.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSIL.BO currently has a P/E ratio of 40.98, whereas NOVATEOR.BO's P/E ratio is 520.17. In terms of profitability, HSIL.BO's ROE is +0.11%, compared to NOVATEOR.BO's ROE of N/A. Regarding short-term risk, HSIL.BO is more volatile compared to NOVATEOR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HSIL.BO.Check NOVATEOR.BO's competition here